From Yahoo Finance! 7:31 am Auxilium Pharma announces positive data from Phase 2a study of CCH In patients with cellulite; mid and high level doses demonstrate statistically significant improvement in cellulite across all endpoints (AUXL) : Co announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy, commonly known as cellulite. In the Phase 2a trial, all three doses of CCH (low (0.06mg), mid (0.48mg) and high (0.84mg)) showed an improvement in the appearance of cellulite as measured by the trial endpoints of an investigator and a patient score on the Global Aesthetic Improvement Scale (:GAIS), which was adapted by the co for use in cellulite. The mid and high dose groups demonstrated a statistically significant improvement in the appearance of cellulite, as measured by GAIS scores, with a p-value of In the mid and high dose groups, 68% of patients reported being Satisfied or Very Satisfied with the results of their treatment, compared to only 34% of patients randomized to placebo. Positive and consistent results were also demonstrated across the trials other endpoints, including Physician and Patient assessed Composite Responder Analyses. CCH was well-tolerated by all dose groups with most adverse events (AEs) being mild to moderate and primarily limited to the local injection area. finance.yahoo/news/inplay-briefing-com-055139997.html#auxl
Posted on: Fri, 22 Aug 2014 06:49:50 +0000
Trending Topics
Recently Viewed Topics
© 2015